Genomma Lab Internacional. de Future Growth
Future criteria checks 5/6
Genomma Lab Internacional. de is forecast to grow earnings and revenue by 20% and 9.9% per annum respectively. EPS is expected to grow by 19% per annum. Return on equity is forecast to be 22.2% in 3 years.
Key information
20.0%
Earnings growth rate
19.0%
EPS growth rate
| Pharmaceuticals earnings growth | 19.6% |
| Revenue growth rate | 9.9% |
| Future return on equity | 22.2% |
| Analyst coverage | Low |
| Last updated | 30 Oct 2024 |
Recent future growth updates
Recent updates
Genomma Lab Internacional. de (BMV:LABB) Has A Pretty Healthy Balance Sheet
Oct 17
Calculating The Intrinsic Value Of Genomma Lab Internacional, S.A.B. de C.V. (BMV:LABB)
Sep 11With Genomma Lab Internacional, S.A.B. de C.V. (BMV:LABB) It Looks Like You'll Get What You Pay For
Jul 12These 4 Measures Indicate That Genomma Lab Internacional. de (BMV:LABB) Is Using Debt Reasonably Well
May 31Here's Why Genomma Lab Internacional. de (BMV:LABB) Can Manage Its Debt Responsibly
Jan 29Is Genomma Lab Internacional, S.A.B. de C.V. (BMV:LABB) Trading At A 49% Discount?
Nov 07Is Genomma Lab Internacional. de (BMV:LABB) Using Too Much Debt?
Mar 31Is Genomma Lab Internacional, S.A.B. de C.V. (BMV:LABB) Trading At A 32% Discount?
Feb 24Does Genomma Lab Internacional. de (BMV:LABB) Have A Healthy Balance Sheet?
Dec 07Rainbows and Unicorns: Genomma Lab Internacional, S.A.B. de C.V. (BMV:LABB) Analysts Just Became A Lot More Optimistic
Sep 24Analysts Just Made A Major Revision To Their Genomma Lab Internacional, S.A.B. de C.V. (BMV:LABB) Revenue Forecasts
Aug 01Genomma Lab Internacional. de (BMV:LABB) Has A Pretty Healthy Balance Sheet
Jul 27Here's Why Genomma Lab Internacional. de (BMV:LABB) Can Manage Its Debt Responsibly
Mar 22Are Investors Undervaluing Genomma Lab Internacional, S.A.B. de C.V. (BMV:LABB) By 44%?
Feb 15Genomma Lab Internacional. de (BMV:LABB) Seems To Use Debt Quite Sensibly
Nov 24Here's Why I Think Genomma Lab Internacional. de (BMV:LABB) Is An Interesting Stock
Sep 08Genomma Lab Internacional, S.A.B. de C.V.'s (BMV:LABB) Intrinsic Value Is Potentially 96% Above Its Share Price
Jun 10Is Genomma Lab Internacional. de (BMV:LABB) A Risky Investment?
May 24Should You Be Adding Genomma Lab Internacional. de (BMV:LABB) To Your Watchlist Today?
May 06Investors Who Bought Genomma Lab Internacional. de (BMV:LABB) Shares Five Years Ago Are Now Up 65%
Mar 13Genomma Lab Internacional. de (BMV:LABB) Has A Pretty Healthy Balance Sheet
Feb 19Do Its Financials Have Any Role To Play In Driving Genomma Lab Internacional, S.A.B. de C.V.'s (BMV:LABB) Stock Up Recently?
Feb 02Are Investors Undervaluing Genomma Lab Internacional, S.A.B. de C.V. (BMV:LABB) By 42%?
Jan 15What Is The Ownership Structure Like For Genomma Lab Internacional, S.A.B. de C.V. (BMV:LABB)?
Dec 28Genomma Lab Internacional. de (BMV:LABB) Shareholders Have Enjoyed A 54% Share Price Gain
Dec 10
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 21,112 | 2,771 | 2,078 | N/A | 4 |
| 12/31/2025 | 19,617 | 2,397 | 2,277 | N/A | 5 |
| 12/31/2024 | 18,271 | 2,172 | 1,667 | N/A | 2 |
| 9/30/2024 | 17,466 | 1,603 | 2,254 | 2,569 | N/A |
| 6/30/2024 | 16,767 | 1,313 | 1,443 | 1,767 | N/A |
| 3/31/2024 | 16,486 | 1,045 | 1,741 | 1,810 | N/A |
| 12/31/2023 | 16,467 | 1,085 | 1,920 | 2,247 | N/A |
| 9/30/2023 | 17,074 | 1,392 | 1,436 | 1,775 | N/A |
| 6/30/2023 | 17,030 | 1,421 | 1,133 | 1,519 | N/A |
| 3/31/2023 | 16,983 | 1,408 | 934 | 1,347 | N/A |
| 12/31/2022 | 16,820 | 1,389 | 1,632 | 2,055 | N/A |
| 9/30/2022 | 16,778 | 1,359 | 1,821 | 2,409 | N/A |
| 6/30/2022 | 16,412 | 1,353 | 1,895 | 2,559 | N/A |
| 3/31/2022 | 15,954 | 1,328 | 1,593 | 2,327 | N/A |
| 12/31/2021 | 15,487 | 1,308 | 632 | 1,468 | N/A |
| 9/30/2021 | 14,868 | 1,352 | 778 | 1,495 | N/A |
| 6/30/2021 | 14,312 | 1,368 | 572 | 1,283 | N/A |
| 3/31/2021 | 14,083 | 1,416 | 580 | 1,316 | N/A |
| 12/31/2020 | 13,870 | 1,404 | 1,010 | 1,715 | N/A |
| 9/30/2020 | 13,619 | 1,179 | 404 | 1,268 | N/A |
| 6/30/2020 | 13,268 | 1,003 | 522 | 1,337 | N/A |
| 3/31/2020 | 12,910 | 886 | 494 | 1,277 | N/A |
| 12/31/2019 | 12,713 | 750 | 130 | 1,007 | N/A |
| 9/30/2019 | 12,617 | 935 | 66 | 1,319 | N/A |
| 6/30/2019 | 12,274 | 925 | -335 | 1,229 | N/A |
| 3/31/2019 | 11,921 | 986 | -87 | 1,551 | N/A |
| 12/31/2018 | 11,794 | 1,109 | 50 | 1,562 | N/A |
| 9/30/2018 | 11,556 | 1,242 | 418 | 1,352 | N/A |
| 6/30/2018 | 11,900 | 1,249 | N/A | 1,214 | N/A |
| 3/31/2018 | 11,886 | 1,218 | N/A | 1,189 | N/A |
| 12/31/2017 | 12,078 | 1,279 | N/A | 1,392 | N/A |
| 9/30/2017 | 11,898 | 958 | N/A | 1,293 | N/A |
| 6/30/2017 | 11,741 | 1,212 | N/A | 1,326 | N/A |
| 3/31/2017 | 11,669 | -1,603 | N/A | 1,459 | N/A |
| 12/31/2016 | 11,316 | -1,681 | N/A | 1,543 | N/A |
| 9/30/2016 | 11,287 | -3,447 | N/A | 1,388 | N/A |
| 6/30/2016 | 10,988 | -3,759 | N/A | 1,571 | N/A |
| 3/31/2016 | 11,125 | -895 | N/A | 587 | N/A |
| 12/31/2015 | 11,042 | -1,137 | N/A | 1,188 | N/A |
| 9/30/2015 | 11,211 | 1,109 | N/A | 1,577 | N/A |
| 6/30/2015 | 11,946 | 1,410 | N/A | 1,600 | N/A |
| 3/31/2015 | 11,871 | 1,396 | N/A | 1,338 | N/A |
| 12/31/2014 | 11,541 | 1,432 | N/A | 1,039 | N/A |
| 9/30/2014 | 12,375 | 1,776 | N/A | 1,081 | N/A |
| 6/30/2014 | 12,082 | 1,766 | N/A | 1,230 | N/A |
| 3/31/2014 | 11,715 | 1,775 | N/A | 1,898 | N/A |
| 12/31/2013 | 11,361 | 1,752 | N/A | 1,871 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: LAB B's forecast earnings growth (20% per year) is above the savings rate (8.1%).
Earnings vs Market: LAB B's earnings (20% per year) are forecast to grow faster than the MX market (11.3% per year).
High Growth Earnings: LAB B's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: LAB B's revenue (9.9% per year) is forecast to grow faster than the MX market (7.1% per year).
High Growth Revenue: LAB B's revenue (9.9% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: LAB B's Return on Equity is forecast to be high in 3 years time (22.2%)